We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.
We are looking for D/P's in the following categories:
ID # | Required D/P's | Enrolled D/P's | Remaining D/P's | Inclusion Criteria |
---|---|---|---|---|
340639 | 1000 | 1 | 999 | Protocol: COL-RESP-528_Testeng services for samples collected at external facilities |
340638 | 1000 | 0 | 1000 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami |
340210 | 3 | 3 | 0 | Pre-Selected HCV Genotype Samples from Inventory |
339974 | 3 | 6 | -3 | Pre-Selected HCV Genotype 4 Samples from Inventory |
339914 | 3 | 5 | -2 | Pre-Selected Anti-HBc Positive Serum Samples from Inventory |
339838 | 100 | 1 | 99 | Urine samples from CT/GC Positive Donors |
339834 | 10 | 1 | 9 | Self-collected vaginal swab samples from CT/GC Positive Donors |
339522 | 20 | 25 | -5 | Pre-Selected Serum Samples from Inventory |
339371 | 3 | 3 | 0 | Pre-Selected HSV-2 Negative Serum samples from Inventory |
339357 | 7 | 7 | 0 | Pre-Selected HSV-2 Positive Serum samples from Inventory |
339238 | 50 | 56 | -6 | Pre-selected HxV Negative Serum from Young Adults (non-smoking) from Inventory |
339042 | 159 | 2 | 157 | HxV-VL Testing in Abbott m2000 |
338900 | 30 | 15 | 15 | High Volume K3EDTA Plasma Collection From Healthy Donors TZC0087368/SRF_0003346 |
338862 | 1 | 3 | -2 | Pre-selected HCV Positive Samples with High Viral Load |
338317 | 32 | 29 | 3 | Pre-Selected Trep and/or RPR Positive Samples from Inventory |
338316 | 5 | 5 | 0 | Pre-Selected Trep and RPR Negative Samples from Inventory |
337877 | 5 | 2 | 3 | Pre-Selected HIV-2 Positive Samples from Inventory |
337876 | 8 | 5 | 3 | Pre-Selected RPR Positive Samples from Inventory |
337875 | 2 | 2 | 0 | Pre-Selected HBsAg positive samples from Inventory. |
337519 | 1 | 1 | 0 | Pre-Selected Flu A Positive Dry Swabs from Inventory |
337518 | 2 | 3 | -1 | Pre-Selected Flu B Positive Dry Swabs from Inventory |
337517 | 14 | 14 | 0 | Pre-Selected COVID Positive Dry Swabs from Inventory |
337401 | 4 | 3 | 1 | Pre-Selected Anti-HBc Positive Samples from Inventory |
337185 | 47 | 45 | 2 | Pre-Selected HIV-1 Positive Samples with CD4 count within 200-499 from Inventory |
336950 | 250 | 54 | 196 | Pre-Selected HIV-2 Viral Load sample for screening. |
336858 | 250 | 250 | 0 | Pre-Selected HIV-2 High Risk Samples Collected in West Africa from Inventory |
336856 | 60 | 55 | 5 | Collection protocol for Panel construction (Custom HxV panels, Q_17332) |
336799 | 100 | 102 | -2 | Self Collected Vaginal Swabs from Symptomatic Donors |
335726 | 100 | 5 | 95 | SARS-CoV-2, Flu A, Flu B, and RSV Positive Nasal, Oropharyngeal, Nasopharyngeal and Blood Collection Protocol |
335646 | 2 | 2 | 0 | Pre-Selected HBV Viral Load Serum Samples from Inventory |
335640 | 110 | 293 | -183 | Pre-Selected HCV Viral Load Serum Samples from Inventory |
335624 | 110 | 6 | 104 | Pre-Selected HIV-2 Viral Load Plasma samples from Inventory |
335606 | 110 | 62 | 48 | Pre-Selected HIV-1 Viral Load Serum samples from Inventory |
335599 | 110 | 76 | 34 | Pre-Selected HIV-1 Hight Viral Load Plasma samples from Inventory |
334050 | 300 | 98 | 202 | Female Vaginal Sample Collection Protocol for CT/GC Symptomatic donors |
333600 | 41 | 41 | 0 | Pre-Selected UTI Positive Urine samples from Inventory |
331596 | 115 | 20 | 95 | Prospective collection from Healthy Donors |
330660 | 80 | 80 | 0 | CT/GC panels to be tested in Abbott and Binx |
329522 | 4338 | 4402 | -64 | Disposition of BioRepository Samples -Urine Negative samples from Talents |
329373 | 100 | 0 | 100 | Prospective Blood Collection Protocol from with elevated ALT levels (>200 IU/L) and Symptomatic of HAV infection. Symptoms: Jaundice, ALT levels >200 IU/L, Fever, Fatigue, Loss of appetite Nausea, Vomiting, Abdominal pain, Dark urine, Diarrhea, Clay-colored stool and Joint pain. |
327905 | 50 | 6 | 44 | Serum and Plasma samples from Pregnant donors with a high risk of HSV-2 Infection. |
326193 | 20 | 1 | 19 | Vaginal Swabs from Chlamydia Trachomatis Positive Donors |
324122 | 100 | 746 | -646 | Pre-selected Samples for Abbott (Generic JR) |
323992 | 8 | 0 | 8 | Pre-Selected Covid Negative Plasma Samples from HxV negative donors. De Pruebaaa |
321260 | 50 | 10 | 40 | Prospective collection from Healthy Donors |
321096 | 22 | 28 | -6 | Pre-Selected EBV positive samples (Antibodies) |
319565 | 80 | 31 | 49 | HIV, HCV, HBV and Syphilis cassette Testing using samples from our Inventory. |
317251 | 100 | 48 | 52 | Pre-Selected CMV samples with Viral Load |
316979 | 100 | 100 | 0 | Pre-Selected Treponema pallidum positive samples |
316965 | 100 | 26 | 74 | HxV-VL Testing in Abbott m2000 |
312456 | 1000 | 200 | 800 | Protocol: COL-RESP-528_Testeng services for samples collected at external facilities |
311816 | 600 | 1000 | -400 | Protocol: LIA-STI-497- Cobas CT/NG/MG Nucleic Acid Test for use on the Cobas Liat System: Clinical Performance Evaluation |
305552 | 1000 | 128 | 872 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami |
303165 | 80 | 0 | 80 | Prospective Rectal Swab Collection |
301909 | 800 | 1007 | -207 | Abbott RealTime CT/NG Testing, Cepheid_248C |
299865 | 30 | 304 | -274 | Nasal Collection Protocol for Flu A/FluB positive donors |
299254 | 60 | 95 | -35 | Cervical and Vaginal Swabs from HPV Positive and Negative Donors |
293753 | 60 | 19 | 41 | Female Vaginal Sample Collection Protocol for CT/GC positive donors |
293648 | 30 | 13 | 17 | Prospective Collection for subjects with CoV-2, Flu A, Flu B, RSV |
292590 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Nasal Swab, Pharyngeal Swab, Vaginal Swab, Rectal Swab, Lesion Swab, Saliva Sample and/or Blood Samples from a positive or suspected positive D/Ps with Monkeypox |
283190 | 200 | 113 | 87 | Protocol No. LIA-STI-250 - cobas CT/NG/MG Nucleic acid test for use on the cobas Liat System: Feasibility Performance Evaluation |
282613 | 100 | 0 | 100 | Rapigen-001 - Clinical Study Protocol - BIOCREDIT COVID-19 Ag Home Test Nasal (Puerto Rico) |
282610 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Sample Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
266931 | 120 | 17 | 103 | PAS-19SUST053 Testing HBV VL (Abbott & Hologic) |
266866 | 120 | 26 | 94 | Protocol: FD-001 - Clinical Evaluation of the Fosun COVID-19 Ag Home Test In Symptomatic and Asymptomatic Subjects |
261154 | 800 | 1892 | -1092 | Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation |
251350 | 100 | 44 | 56 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
242206 | 5000 | 27665 | -22665 | COVID-19 Testing |
239188 | 500 | 0 | 500 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
227994 | 130 | 5 | 125 | PAS-19SUST054 - HCV |
225611 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
224514 | 600 | 76 | 524 | Initiative to Screen Potential Study Candidates (SUST) |
190737 | 5000 | 67 | 4933 | SARS-CoV-2 Survey (PT) |
182696 | 1000 | 355 | 645 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections |
175121 | 1000 | 27 | 973 | CBC Initiative |
173768 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects |
152854 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
151681 | 5000 | 3 | 4997 | Refer to Processing Instructions @ Attachment Tab |
149547 | 5000 | 320 | 4680 | Refer to Processing Instructions @ Attachment Tab TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB |
148791 | 5000 | 48 | 4952 | Refer to Processing Instructions @ Attachment Tab |
145574 | 5000 | 130 | 4870 | Refer to Processing Instructions @ Attachment Tab |
144620 | 5000 | 61 | 4939 | Refer to Processing Instructions @ Attachment Tab |
142755 | 5000 | 132 | 4868 | Refer to Processing Instructions @ Attachment Tab |
141914 | 1000 | 7 | 993 | HIV Initiative |
141493 | 5000 | 60 | 4940 | HCV Viral Load and Genotype Survey (PT) |
141491 | 5000 | 24 | 4976 | HBV Viral Load Survey (PT) |
141490 | 5000 | 60 | 4940 | HIV Viral Load Survey (PT) |
140923 | 5000 | 125 | 4875 | Refer to Processing Instructions @ Attachment Tab |
140922 | 5000 | 65 | 4935 | Refer to Processing Instructions @ Attachment Tab |
140530 | 5000 | 10 | 4990 | Rubella IgG (AAB - PT) |
140528 | 5000 | 6 | 4994 | ToRCH (AAB - PT) |
139409 | 5000 | 137 | 4863 | Pregnancy (PT) |
137933 | 5000 | 0 | 5000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
129688 | 200 | 163 | 37 | EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia |
129538 | 1000 | 309 | 691 | RPR Initiative |
128402 | 1000 | 73 | 927 | CBC Initiative |
124266 | 5000 | 143 | 4857 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire |
122931 | 5000 | 3767 | 1233 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
122654 | 5000 | 171 | 4829 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland |
120851 | 140 | 26 | 114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
109382 | 100 | 32 | 68 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
109381 | 300 | 6 | 294 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
108692 | 1000 | 1178 | -178 | HxV Testing Initiative |
102419 | 1000 | 503 | 497 | Samples on hold for future shipments to China |
98830 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples |
98084 | 1000 | 577 | 423 | CBC Qualifying Job Request |
96278 | 195 | 185 | 10 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
96055 | 40 | 2132 | -2092 | Hologic Panels for HIV and HCV |
94841 | 500 | 1 | 499 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR |
80997 | 5000 | 428 | 4572 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
78138 | 300 | 140 | 160 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
78137 | 300 | 414 | -114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
74261 | 10000 | 0 | 10000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
68258 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
63868 | 1000 | 1386 | -386 | Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau |
56717 | 20000 | 0 | 20000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples |
55075 | 10000 | 28 | 9972 | Beta HCG Matched Set Prospective Blood Collection Protocol |
54664 | 200 | 148 | 52 | Random Cadaveric Samples |
27615 | 15000 | 633 | 14367 | Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World |
26761 | 10000 | 482 | 9518 | HIV Positive Time Stability Whole Blood Collection Protocol |
10694 | 3000 | 2234 | 766 | HCV Longitudinal Prospective Blood Collection Protocol |
10693 | 3000 | 369 | 2631 | HBV Multi-Point Prospective Blood Collection Protocol |
8568 | 300 | 1750 | -1450 | Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV) |
BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.
You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.